These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

729 related articles for article (PubMed ID: 18422610)

  • 21. Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China.
    Tang L; Wu R; Sun J; Zhang X; Feng X; Zhang X; Luke KH; Poon MC
    Haemophilia; 2013 Jan; 19(1):27-34. PubMed ID: 23231016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Including the life-time cumulative number of joint bleeds in the definition of primary prophylaxis.
    den Uijl IE; Fischer K
    Thromb Haemost; 2008 May; 99(5):965; author reply 966-8. PubMed ID: 18449430
    [No Abstract]   [Full Text] [Related]  

  • 23. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens.
    Collins PW; Björkman S; Fischer K; Blanchette V; Oh M; Schroth P; Fritsch S; Casey K; Spotts G; Ewenstein BM
    J Thromb Haemost; 2010 Feb; 8(2):269-75. PubMed ID: 19943875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
    Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
    N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy.
    Coppola A; D'Ausilio A; Aiello A; Amoresano S; Toumi M; Mathew P; Tagliaferri A;
    Haemophilia; 2017 May; 23(3):422-429. PubMed ID: 28181369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison between prophylaxis and on demand treatment for severe haemophilia.
    Khoriaty R; Taher A; Inati A; Lee C
    Clin Lab Haematol; 2005 Oct; 27(5):320-3. PubMed ID: 16178913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Valuing reduced antibiotic use for pediatric acute otitis media.
    Meropol SB
    Pediatrics; 2008 Apr; 121(4):669-73. PubMed ID: 18381529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of children with severe haemophilia A and inhibitors: a health economic evaluation for Germany.
    Berger K; Schopohl D; Eheberg D; Auerswald G; Kurnik K; Schramm W
    Klin Padiatr; 2013 May; 225(3):152-8. PubMed ID: 23519749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS, COMPARED WITH ON-DEMAND TREATMENT, FOR PATIENTS WITH SEVERE HEMOPHILIA TYPE A IN COLOMBIA.
    Castro Jaramillo HE; Moreno Viscaya M; Mejia AE
    Int J Technol Assess Health Care; 2016 Jan; 32(5):337-347. PubMed ID: 27919309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors.
    Ullman M; Hoots WK
    Haemophilia; 2006 Dec; 12 Suppl 6():74-9; discussion 79-80. PubMed ID: 17123398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials.
    Fischer K; Collins P; Björkman S; Blanchette V; Oh M; Fritsch S; Schroth P; Spotts G; Ewenstein B
    Haemophilia; 2011 May; 17(3):433-8. PubMed ID: 21299740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Haemophilia care in children--benefits of early prophylaxis for inhibitor prevention.
    Mancuso ME; Graca L; Auerswald G; Santagostino E
    Haemophilia; 2009 Jan; 15 Suppl 1():8-14. PubMed ID: 19125935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
    Henry N; Jovanović J; Schlueter M; Kritikou P; Wilson K; Myrén KJ
    J Med Econ; 2018 Apr; 21(4):318-325. PubMed ID: 29139314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Healthcare resource utilization among haemophilia A patients in the United States.
    Valentino LA; Pipe SW; Tarantino MD; Ye X; Xiong Y; Luo MP
    Haemophilia; 2012 May; 18(3):332-8. PubMed ID: 22044662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A.
    Zhou ZY; Raimundo K; Patel AM; Han S; Ji Y; Fang H; Zhong J; Betts KA; Mahajerin A
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1109-1120. PubMed ID: 32452276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.
    Xie F; Blackhouse G; Assasi N; Campbell K; Levin M; Bowen J; Tarride JE; Pi D; Goeree R
    Clin Ther; 2009 May; 31(5):1082-91; discussion 1066-8. PubMed ID: 19539109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens.
    Berntorp E
    Haemophilia; 2009 Nov; 15(6):1219-27. PubMed ID: 19659939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United States.
    Thornburg CD; Carpenter S; Zappa S; Munn J; Leissinger C
    Haemophilia; 2012 Jul; 18(4):568-74. PubMed ID: 22335526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose and outcome of care in haemophilia--how do we define cost-effectiveness?
    Fischer K; Van den Berg HM; Thomas R; Kumar S; Poonnoose P; Viswabandya A; Mathews V; Kavitha ML; Bhattacharji S; Srivastava A
    Haemophilia; 2004 Oct; 10 Suppl 4():216-20. PubMed ID: 15479401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
    Ahnström J; Berntorp E; Lindvall K; Björkman S
    Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.